Nektar Therapeutics (NKTR) Short term Debt (2011 - 2020)
Nektar Therapeutics (NKTR) posted quarterly Short term Debt of $254.1 million for Q1 2020, little changed quarter-over-quarter from $252.9 million in Q4 2019.
Powered by 
Analysis
Nektar Therapeutics (NKTR) Short term Debt (2011 - 2020) Analysis & Trends
Nektar Therapeutics' Short term Debt history runs 5 years deep, the most recent figure standing at $254.1 million for Q1 2020.
- In Q1 2020, Short term Debt changed N/A year-over-year to $254.1 million; the TTM figure through Mar 2020 stood at $254.1 million (changed N/A YoY), while the FY2019 annual figure was $252.9 million, changed N/A from the prior year.
- Short term Debt for Q1 2020 stood at $254.1 million, roughly flat from $252.9 million in the prior quarter.
- The five-year high for Short term Debt was $254.1 million in Q1 2020, with the low at $252.9 million in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Nektar Therapeutics | 2.45 Bn | 1.77 Bn | 3.04 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 254.14 Mn |
| Dec 31, 2019 | 252.89 Mn |
| Sep 30, 2015 | 125.00 Mn |
| Mar 31, 2012 | 214.96 Mn |
| Dec 31, 2011 | 214.96 Mn |
| Sep 30, 2011 | 214.96 Mn |